Pilar Herrera
A5053626099- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Histone Deacetylase Inhibitors Research
- COVID-19 and healthcare impacts
- COVID-19 Clinical Research Studies
- Neutropenia and Cancer Infections
- Renal Transplantation Outcomes and Treatments
- Single-cell and spatial transcriptomics
- Glioma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Polyomavirus and related diseases
- Congenital Anomalies and Fetal Surgery
- Epigenetics and DNA Methylation
- Drug Transport and Resistance Mechanisms
- HIV/AIDS drug development and treatment
- Childhood Cancer Survivors' Quality of Life
- Congenital Diaphragmatic Hernia Studies
Hospital Universitario Ramón y Cajal
2016-2025
Instituto Ramón y Cajal de Investigación Sanitaria
2024
Hospital Universitario Puerta de Hierro Majadahonda
2022-2024
Instituto Cajal
2020
Hudson Institute
2018
John Wiley & Sons (United States)
2018
Universidad de Alcalá
2018
Instituto Nacional de Pediatria
2015
Universidad del Desarrollo
2008
Hospital Padre Hurtado
2007
Abstract Background Patients with cancer have been shown to a higher risk of clinical severity and mortality compared non-cancer patients COVID-19. hematologic malignancies typically are known levels immunosuppression may develop more severe respiratory viral infections than solid tumors. Data on COVID-19 in limited. Here we characterize disease evaluate potential prognostic factors for mortality. Methods In this population-based registry study, collected de-identified data characteristics,...
The prevalence of cancer in patients with the novel coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 infection, is uncertain. In a pooled meta-analysis including 11 retrospective studies, was 2%.1 Patients and COVID-19 have been reported to higher risk suffering severe events (intensive care unit admission, invasive ventilation, death) study 18 cancer.2 One 13 cases cohort 128 hospitalised haematological cancers, no significant differences baseline co-variates between developing or...
Secondary acute myeloid leukemia (sAML) comprises a heterogeneous group of patients and is associated with poor overall survival (OS). We analyze the characteristics, treatment patterns, outcomes adult sAML in Programa Español de Tratamientos en Hematología (PETHEMA) registry. Overall, 6211 (72.9%) were novo 2310 (27.1%) had sAML, divided into myelodysplastic syndrome AML (MDS-AML, 44%), MDS/myeloproliferative (MDS/MPN-AML, 10%), MPN-AML (11%), therapy-related (t-AML, 25%), antecedent...
A high proportion of patients with acute myeloid leukemia who achieve minimal residual disease negative status ultimately relapse because a fraction pathological clones remains undetected by standard methods. We designed and validated high-throughput sequencing method for assessment cell clonotypes mutations NPM1, IDH1/2 and/or FLT3-single nucleotide variants. For clinical validation, 106 follow-up samples from 63 in complete remission were studied sequencing, evaluating the level detected...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to determine the clinical outcomes assess impact of therapeutic approaches adult AML patients with SARS-CoV-2 first wave (March–May 2020). Overall, 108 were included: 51.9% active 70.4% under schedules for AML. Signs symptoms present 96.3% 82.4% received...
Mortality rates for COVID-19 have declined over time in the general population, but data patients with hematologic malignancies are contradictory. We identified independent prognostic factors severity and survival unvaccinated malignancies, compared mortality versus non-cancer inpatients, investigated post condition. Data were analyzed from 1166 consecutive, eligible population-based HEMATO-MADRID registry, Spain, prior to vaccination roll-out, stratified into early (February-June 2020; n =...
Bcl-2 protein plays a major role in the prevention of programmed cell death differentiating cells. In present study, expression cytoplasmic bcl-2 by human Bone Marrow Mast Cells (BMMC) from both normal and pathological bone marrow samples was examined. A total 35 subjects corresponding to 9 healthy volunteers, 8 cases adult indolent systemic mast disease (SMCD), 4 pediatric mastocytosis (PM), 11 hematological malignancies (HM), 2 reactive marrow, 1 case leukemia (MCL) were analyzed. The...
There are two major forms of the BCR/ABL fusion gene, involving ABL exon 2, but including different exons BCR gene. The transcripts b2a2 or b3a2 code for a p210 protein. Another gene leads to expression an e1a2 transcript, which codes p190 Another, less common is c3a2[e19a2], encodes p230 incidence one other rearrangement in chronic myeloid leukaemia (CML) patients varies reported series. This study was designed determine frequency coexpresion p210, and 250 Mexican with CML. We performed...
We have evaluated the ex vivo pharmacology of single drugs and drug combinations in malignant cells bone marrow samples from 125 patients with acute myeloid leukemia using a novel automated flow cytometry-based platform (ExviTech). improved previous testing 4 innovations: identifying individual leukemic cells, intact whole blood during incubation, an that escalates reliably data, performing analyses pharmacodynamic population models.Samples were sent 24 hospitals to central laboratory...
BACKGROUND Options to treat elderly patients (≥65 years old) newly diagnosed with acute myeloid leukemia (AML) include intensive and attenuated chemotherapy, hypomethylating agents or without venetoclax, supportive care. This multicenter, randomized, open‐label, phase 3 trial was designed assess the efficacy safety of a fludarabine, cytarabine, filgrastim (FLUGA) regimen in comparison azacitidine (AZA). METHODS Patients (n = 283) were randomized 1:1 FLUGA 141) AZA 142). Response evaluated...
Abstract The value of measurable residual disease (MRD) in elderly patients with acute myeloid leukemia (AML) is inconsistent between those treated intensive vs hypomethylating drugs, and unknown after semi-intensive therapy. We investigated the role MRD refining complete remission (CR) treatment duration phase 3 FLUGAZA clinical trial, which randomized 283 AML to induction consolidation fludarabine plus cytarabine (FLUGA) 5-azacitidine. After consolidation, continued if was ≥0.01% or...
Background Donor specific antibodies (DSAs) can be responsible for graft failure (GF) in the setting of mismatched hematopoietic stem cell transplantation (HSCT). The aim our study is to report experience Madrid Group Hematopoietic Transplant (GMTH) patients with DSAs undergoing haplo-HSCT. Methods Patients haplo-HSCT centers from GMTH 2012 2020 were included study. analyzed a solid-phase single-antigen immunoassay; monitoring was performed during desensitization on days -14, -7, 0 and...
SARS-CoV-2 infection has bimodal distribution in Europe with a first wave March to June 2020 and second September February 2021. We compared the frequency, clinical characteristics outcomes of adults acute lymphoblastic leukemia (ALL) vs. pandemic waves Spain.In this prospective study ALL COVID-19 infection, comorbidities, treatment outcome two periods were compared. The ended when vaccination against was implemented Spain.Twenty eight patients collected 24 second. median age 46.5 years...
Post-transplantation cyclophosphamide (PTCY) effectively prevents graft-versus-host disease (GVHD) after unmanipulated HLA-haploidentical hematopoietic stem cell transplantation (HSCT) and achieves low rates of GVHD in HLA-identical transplantation. To compare the outcomes haploidentical versus HLA identical HSCT patients undergoing for acute myeloid leukemia (AML) using PTCY. We conducted a retrospective study 229 first AML PTCY with additional immunosuppression, 99 from matched sibling or...
A greater understanding of clinical trends in COVID-19 outcomes among patients with hematologic malignancies (HM) over the course pandemic, particularly Omicron era, is needed. This ongoing, observational, and registry-based study prospective data collection evaluated severity mortality 1818 adult HM diagnosed between 27 February 2020 1 October 2022, at 31 centers Madrid region Spain. Of these, 1281 (70.5%) 537 (29.5%) were reported pre-Omicron periods, respectively. Overall, aged ≥70 years...
High dose-intensive or infusional intermediate-dose immunochemotherapy is highly effective treatment for Burkitt lymphoma irrespective of human immunodeficiency virus (HIV) infection. However, toxicities these regimens are relevant, especially in older adults and elderly patients. The prospective multicenter BURKIMAB14 trial included four to six blocks according stage (localized: 1 2 non-bulky; advanced: bulky, 3, 4) age, with dose reduction patients >55 years old. Dose-intensity...